Lindsay Fischer

Articles

Fostering Interactions That Heal

January 5th 2024

The pain and suffering that Eduardo Bruera, MD, FAAHPM, witnessed in patients during his clinical oncology rotations motivated him to reshape palliative care treatment.

Revumenib Elicits High Response Rate in R/R KMT2A-Rearranged Acute Leukemia

December 12th 2023

Revumenib demonstrated clinically meaningful activity, including high response and minimal residual disease negativity rates, in heavily pretreated patients with KMT2A-rearranged acute leukemia.

Safety of Outpatient CAR T-Cell Therapy May Be Improved With Integrated Management Process

December 10th 2023

The utilization of remote patient monitoring within the first 30 days of outpatient CAR T-cell therapy can promote patient safety, reduce costs, and decrease hospitalization rates by allowing patients with hematologic malignancies to connect with a virtual care platform.

Endocrine Therapy Response Status Is Necessary for Treatment Planning in HR+/HER2– Early Breast Cancer

December 9th 2023

Beyond genomic testing, endocrine therapy response should be used to determine whether patients with hormone receptor–positive, HER2-negative, N0-1 early breast cancer.

Alectinib Elicits DFS Benefit in Early-Stage, Resected, ALK+ NSCLC

October 21st 2023

Treatment with the oral ALK inhibitor alectinib led to a statistically significant improvement in disease-free survival in patients with resected ALK-positive non–small cell lung cancer.

On-Pathway Regimens Are Associated With Significant Cost Savings for Treatment of Solid Tumors

August 17th 2023

Findings from a cross-institutional study suggest that on-pathway regimens led to significant cost savings for patients with cancer, despite the rate of hospitalizations and immune-related adverse events being similar between on-pathway and off-pathway regimens.

Stereotactic Ablative Body Radiotherapy Yields Long-Term Disease Control in Lung Oligometastases Regardless of Fractionation Schedule

August 4th 2023

Single-fraction stereotactic ablative body radiotherapy generated overall survival outcomes comparable to those achieved with multifraction SABR in patients with lung oligometastases.

Surgery and Radiotherapy Generate Similar Long-Term PROs in OPSCC

July 22nd 2023

Long-term assessments did not reveal differences in patient-reported outcomes between primary surgery or radiotherapy for patients with oropharyngeal squamous cell carcinoma.

Older Patients Experience Functional Recovery 3 Months After Major Surgery for CRC

July 21st 2023

Three months following a major colorectal cancer surgery, the majority of older patients achieved functional recovery.

FOLFOX Produces Varying Toxicity Profile vs Chemoradiation in Rectal Cancer

July 1st 2023

Lower rates of diarrhea and overall bowel dysfunction were reported with the use of neoadjuvant fluorouracil and oxaliplatin vs neoadjuvant pelvic chemoradiation with fluorouracil (5FCURT) in patients with locally advanced rectal cancer. However, lower rates of other toxicities were reported in patients treated with 5FCURT.

SONIA Trial Suggests Second-line Use May Be Optimal for CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

June 24th 2023

The second line may be the optimal setting for patients with HR-positive, HER2-negative advanced breast cancer to receive CDK4/6 inhibitors plus an aromatase inhibitor followed by fulvestrant.

ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL

June 6th 2023

Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.

PRO Outcomes With Dostarlimab/Chemo Similar to Chemo Alone in 3-Year Follow-Up of Patients With Endometrial Cancer

June 4th 2023

Dostarlimab maintained the health-related quality of life in patients with primary advanced or recurrent endometrial cancer.

HIMALAYA Safety Data Support STRIDE Regimen as A Global Treatment Option for uHCC

June 3rd 2023

Patients with unresectable hepatocellular carcinoma experienced manageable and low-grade immune-related adverse events with single tremelimumab regular interval durvalumab.

Venetoclax Plus Obinutuzumab With or Without Ibrutinib Improves Undetectable MRD Rates in Fit Patients With CLL

May 27th 2023

The combination of venetoclax and obinutuzumab with or without ibrutinib generated higher rates of undetectable minimal residual disease (MRD) and progression-free survival vs chemoimmunotherapy in fit patients with chronic lymphocytic leukemia.

Cabozantinib Plus Nivolumab and Ipilimumab Provides PFS Benefit in Advanced RCC

May 20th 2023

The addition of cabozantinib to nivolumab and ipilimumab led to improved progression-free survival vs nivolumab and ipilimumab alone in patients with treatment-naïve advanced renal cell carcinoma; however, the rate of grade 3/4 adverse effects with the triplet was 79%.

Elacestrant PROs Consistent With Standard of Care Endocrine Therapy in Patients With Metastatic Breast Cancer

May 11th 2023

Elacestrant maintained the quality of life for patients with metastatic breast cancer for at least 6 treatment cycles, according to patient reported outcomes.

Novel Methylation-Based Platform Shows Promise for Multicancer Early Detection

April 21st 2023

A genome-wide methylome enrichment platform demonstrated efficacy in detecting early-stage, low-shedding cancers with limited circulating tumor DNA.

Exome Sequencing Is A Feasible Way to Execute CDCT1 Genetic Condition Screening

April 18th 2023

Whole-exome sequencing successfully identified genetic conditions in patients who may have been missed by clinical guidelines.

Carolina Frailty Index Score Shows Utility in Ovarian Cancer Setting

March 27th 2023

Women with ovarian cancer may be effectively assessed for frailty status via the Carolina Frailty Index Score.